Alliancebernstein L.P. Halozyme Therapeutics, Inc. Transaction History
Alliancebernstein L.P.
- $278 Billion
- Q2 2024
A detailed history of Alliancebernstein L.P. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 3,549,075 shares of HALO stock, worth $212 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
3,549,075
Previous 3,666,324
3.2%
Holding current value
$212 Million
Previous $149 Million
24.6%
% of portfolio
0.07%
Previous 0.05%
Shares
27 transactions
Others Institutions Holding HALO
# of Institutions
526Shares Held
123MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.05 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$769 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$347 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$241 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.13MShares$187 Million0.28% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.3B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...